Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27330609 | 0.94 | HSD17B10 (0.67) | HSD17B10ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL29299643 | 0.91 | HSD17B10 (0.41) | HSD17B10ALDH1A1 | |
| SCHEMBL29299640 | 0.91 | HSD17B10 (0.41) | HSD17B10ALDH1A1 | |
| SCHEMBL27330714 | 0.89 | HSD17B10 (0.74) | HSD17B10ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL27315572 | 0.89 | HSD17B10 (0.74) | HSD17B10ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL29299636 | 0.86 | SIGMAR1 (0.38) | HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL12158507 | 0.85 | KDM4E (0.55) | HSD17B10ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL27330598 | 0.84 | HSD17B10 (0.54) | HSD17B10ALDH1A1KDM4EALOX15TSHR | |
| SCHEMBL24220956 | 0.83 | HSD17B10 (0.47) | HSD17B10ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10284339 | 0.83 | HSD17B10 (0.47) | HSD17B10ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885ALDH1A1 3906/4885KDM4E 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.